

Michael H Barnett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3428170/publications.pdf>

Version: 2024-02-01

136
papers

6,931
citations

94269

37
h-index

64668

79
g-index

142
all docs

142
docs citations

142
times ranked

7129
citing authors

#	ARTICLE	IF	CITATIONS
1	Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. <i>Annals of Neurology</i> , 2004, 55, 458-468.	2.8	1,042
2	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 127-137.	0.9	422
3	Immunopathology of secondary-progressive multiple sclerosis. <i>Annals of Neurology</i> , 2001, 50, 646-657.	2.8	371
4	Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. <i>Annals of Neurology</i> , 2009, 66, 739-753.	2.8	335
5	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 470-482.	1.4	284
6	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
7	Exosomal microRNA signatures in multiple sclerosis reflect disease status. <i>Scientific Reports</i> , 2017, 7, 14293.	1.6	196
8	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e40.	3.1	192
9	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
10	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
11	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.5	138
12	Immunoglobulins and complement in postmortem multiple sclerosis tissue. <i>Annals of Neurology</i> , 2009, 65, 32-46.	2.8	129
13	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 777-793.	1.4	126
14	Atypical inflammatory demyelinating syndromes of the CNS. <i>Lancet Neurology</i> , The, 2016, 15, 967-981.	4.9	121
15	Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. <i>Npj Precision Oncology</i> , 2018, 2, 28.	2.3	116
16	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	0.9	108
17	Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. <i>Neurology</i> , 2014, 82, 2165-2172.	1.5	99
18	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019, 10, 5779.	5.8	87

#	ARTICLE	IF	CITATIONS
19	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641983657.	1.5	83
20	MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?. <i>NeuroImage: Clinical</i> , 2017, 13, 264-270.	1.4	82
21	Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. <i>Brain</i> , 2019, 142, 426-442.	3.7	78
22	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	0.9	76
23	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	1.4	73
24	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. <i>Acta Neuropathologica Communications</i> , 2019, 7, 145.	2.4	71
25	Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Ophthalmology</i> , 2019, 126, 445-453.	2.5	69
26	Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 514-521.	0.9	66
27	Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. , 2016, 57, 2311.		62
28	Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	58
29	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 373-387.	1.7	57
30	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. <i>Frontiers in Neurology</i> , 2019, 10, 1028.	1.1	56
31	Molecular Pathogenesis of Neuromyelitis Optica. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12970-12993.	1.8	54
32	Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 582-584.	0.9	54
33	Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. <i>Ophthalmology</i> , 2019, 126, 801-810.	2.5	54
34	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
35	Decoding Diffusivity in Multiple Sclerosis: Analysis of Optic Radiation Lesional and Non-Lesional White Matter. <i>PLoS ONE</i> , 2015, 10, e0122114.	1.1	52
36	The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, jnnp-2014-309649.	0.9	51

#	ARTICLE	IF	CITATIONS
37	The evolution of “No Evidence of Disease Activity” in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 231-238.	0.9	48
38	Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 754-757.	0.9	47
39	Latency of Multifocal Visual Evoked Potentials in Nonoptic Neuritis Eyes of Multiple Sclerosis Patients Associated With Optic Radiation Lesions. , 2014, 55, 3758.		46
40	Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. <i>NeuroImage: Clinical</i> , 2018, 17, 1028-1035.	1.4	46
41	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
42	Targeting B Cells to Modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	37
43	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36
44	Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment. <i>Molecular Neurobiology</i> , 2020, 57, 1245-1258.	1.9	35
45	Brain Volumetrics, Regional Cortical Thickness and Radiographic Findings in Adults with Cyanotic Congenital Heart Disease. <i>NeuroImage: Clinical</i> , 2014, 4, 319-325.	1.4	34
46	Distinguishing Susac’s syndrome from multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 1613-1621.	1.8	34
47	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
48	Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework. <i>Frontiers in Neuroscience</i> , 2016, 10, 576.	1.4	32
49	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
50	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. <i>Neurology</i> , 2017, 88, 1004-1006.	1.5	30
51	The electrophysiological assessment of visual function in Multiple Sclerosis. <i>Clinical Neurophysiology Practice</i> , 2019, 4, 90-96.	0.6	30
52	Targeting B cells to modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	30
53	Expansion of chronic lesions is linked to disease progression in relapsing “remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1533-1542.	1.4	29
54	Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e427.	3.1	28

#	ARTICLE	IF	CITATIONS
55	Neuromyelitis optica. <i>Current Opinion in Neurology</i> , 2012, 25, 215-220.	1.8	27
56	Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1883-1887.	1.4	27
57	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , 2020, 11, 537.	1.1	27
58	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
59	Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2379-2389.	1.8	26
60	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1033-1043.	0.9	26
61	Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 882-894.	0.9	23
62	Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases. <i>Current Opinion in Neurology</i> , 2016, 29, 213-221.	1.8	22
63	Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions. <i>Journal of Neurology</i> , 2017, 264, 2119-2129.	1.8	22
64	Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	22
65	The spectrum of immune-mediated and inflammatory lesions of the brainstem. <i>Neurology</i> , 2019, 93, 390-405.	1.5	22
66	Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	21
67	Cold Water Ingestion Improves Exercise Tolerance of Heat-Sensitive People with MS. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 643-648.	0.2	18
68	COVID-19 and the Sacrificial International Order. <i>International Organization</i> , 2020, 74, E128-E147.	3.6	18
69	Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 2680-2692.	3.9	18
70	Diffusivity in multiple sclerosis lesions: At the cutting edge?. <i>NeuroImage: Clinical</i> , 2016, 12, 219-226.	1.4	17
71	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443.	1.8	17
72	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 978-985.	0.9	17

#	ARTICLE	IF	CITATIONS
73	BalÃ³'s concentric sclerosis and tumefactive demyelination: A shared immunopathogenesis?. <i>Journal of the Neurological Sciences</i> , 2015, 348, 279-281.	0.3	16
74	Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome. <i>European Journal of Neurology</i> , 2022, 29, 1771-1781.	1.7	16
75	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. <i>Multiple Sclerosis Journal</i> , 2020, 26, 737-740.	1.4	14
76	Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study. <i>PLoS ONE</i> , 2016, 11, e0149245.	1.1	13
77	Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus. <i>Multiple Sclerosis Journal</i> , 2015, 21, 905-915.	1.4	12
78	The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol. <i>BMC Neurology</i> , 2019, 19, 129.	0.8	12
79	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12
80	Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. <i>Journal of Neurology</i> , 2016, 263, 792-798.	1.8	11
81	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
82	Tablet-based screening improves continence management in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 679-687.	1.7	10
83	Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis. <i>Neurology</i> , 2016, 87, 2595-2597.	1.5	10
84	Imaging the multiple sclerosis lesion: insights into pathogenesis, progression and repair. <i>Current Opinion in Neurology</i> , 2019, 32, 338-345.	1.8	10
85	Remyelination Trials. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	10
86	White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. <i>PLoS ONE</i> , 2018, 13, e0191131.	1.1	9
87	The expansion and severity of chronic MS lesions follows a periventricular gradient. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1504-1514.	1.4	9
88	FOD-Net: A deep learning method for fiber orientation distribution angular super resolution. <i>Medical Image Analysis</i> , 2022, 79, 102431.	7.0	9
89	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	1.4	8
90	Diffusivity in the core of chronic multiple sclerosis lesions. <i>PLoS ONE</i> , 2018, 13, e0194142.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019, 29, 615-623.	1.0	8
92	Interferon- β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	8
93	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237.	1.1	8
94	Latency of Multifocal Visual Evoked Potential in Multiple Sclerosis: A Visual Pathway Biomarker for Clinical Trials of Remyelinating Therapies. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 186-191.	0.9	8
95	Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1124-1131.	1.4	7
96	Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 104-107.	0.9	7
97	Neurological manifestations of severe acute respiratory syndrome coronavirus 2 "a controversy "gone viral"™. <i>Brain Communications</i> , 2020, 2, fcaa149.	1.5	7
98	Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102175.	0.9	7
99	Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. <i>Frontiers in Immunology</i> , 2020, 11, 119.	2.2	7
100	Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis. <i>PLoS ONE</i> , 2021, 16, e0244766.	1.1	7
101	Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. <i>Journal of Applied Laboratory Medicine</i> , The, 2022, 7, 12-25.	0.6	7
102	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102849.	0.9	7
103	Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. <i>Multiple Sclerosis Journal</i> , 2022, 28, 697-706.	1.4	7
104	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e2020-e2031.	1.5	7
105	A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1392-1401.	1.4	7
106	Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095735.	0.5	6
107	Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1319-1324.	0.9	6
108	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021, 32, 102802.	1.4	5
110	Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e19309.	2.1	5
111	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. <i>Journal of Neurology</i> , 2022, 269, 836-845.	1.8	5
112	Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	5
113	MRI and laboratory monitoring of disease-modifying therapy efficacy and risks. <i>Current Opinion in Neurology</i> , 2022, 35, 278-285.	1.8	5
114	Spinal nerve root hypertrophy in chronic ataxic neuropathy with antiglycolipid IgM antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 97-97.	0.9	4
115	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). <i>JMIR Research Protocols</i> , 2021, 10, e24969.	0.5	4
116	Masked Multi-Task Network for Case-Level Intracranial Hemorrhage Classification in Brain CT Volumes. <i>Lecture Notes in Computer Science</i> , 2020, , 145-154.	1.0	4
117	Progressive Neuropsychiatric Symptoms and Motor Impairment. <i>JAMA Neurology</i> , 2014, 71, 794.	4.5	3
118	Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data. <i>BMJ Neurology Open</i> , 2022, 4, e000315.	0.7	3
119	Blurred vision and pain in the eye. <i>Medical Journal of Australia</i> , 2011, 195, 329-332.	0.8	2
120	Acute bulbar, neck and limb weakness with monospecific anti-IGF1a antibody: A rare localized subtype of Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2016, 53, 143-146.	1.0	2
121	Rituximab and maintenance mycophenolate mofetil for treatment of refractory ANTI-N-METHYL-D-ASPARTATE-receptor (NMDAR) encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A44.3-A45.	0.9	2
122	We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – Yes. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1272-1274.	1.4	1
123	Core temperature is not elevated at rest in people with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 62-67.	0.9	1
124	Thinking fast not slow: a fast-acting, high-titre acquired factor VIII inhibitor. <i>Pathology</i> , 2021, , .	0.3	1
125	Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 713-714.	0.9	0
126	Estimating the health and economic burden of investigating tumefactive demyelination compared to conventional multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A13.3-A14.	0.9	0

#	ARTICLE	IF	CITATIONS
127	111â€¦Recurrent headaches with psychosis, CSF lymphocytosis, vessel beading and papilloedema-autoimmune/viral encephalitis with vasculopathy or unusual presentation of reversible cerebral vasoconstriction syndrome (RCVS)?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A36.1-A36.	0.9	0
128	091â€¦Cerebellar oedema in fulminant adult leigh syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A29.2-A29.	0.9	0
129	Forearmâ€¦predominant parainfectious myositis. Muscle and Nerve, 2019, 59, E7-E10.	1.0	0
130	Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 2021, 58, 103408.	0.9	0
131	Title is missing!. , 2021, 16, e0244766.		0
132	Title is missing!. , 2021, 16, e0244766.		0
133	Title is missing!. , 2021, 16, e0244766.		0
134	Title is missing!. , 2021, 16, e0244766.		0
135	Title is missing!. , 2021, 16, e0244766.		0
136	Title is missing!. , 2021, 16, e0244766.		0